Q1 Net Loss Widens to $27.7M Amid CAR-T Acquisition; New $2.3M Liquidity Relief from Related Party
TPST sits 28% above its 52-week low of $1.5.
Summary
Tempest Therapeutics reported a $27.7 million net loss for Q1 2026 and reiterated a 'going concern' warning, but secured $2.3 million in new liquidity relief from a related party and completed a $2.0 million private placement.
Key Events · Financing and Capital Events · TPST
-
Going Concern Warning Reiterated
The company reported only $1.8 million in cash and cash equivalents as of March 31, 2026, down from $7.7 million at December 31, 2025, and expects its existing cash to fund operations for less than 12 months, raising substantial doubt about its ability to continue as a going concern.
-
Significant Net Loss Driven by Acquisition Costs
Net loss for Q1 2026 increased to $27.7 million, compared to $10.9 million in Q1 2025. This was primarily due to a $22.2 million non-cash expense for acquired in-process research and development related to the Erigen CAR-T asset acquisition.
-
New Liquidity Relief from Related Party
Subsequent to quarter-end, on May 11, 2026, Factor Bioscience Inc. (a related party) permanently waived $2.1 million in service fees and agreed to return a $0.2 million deposit, providing $2.3 million in immediate liquidity relief.
-
Private Placement Completed
In March 2026, the company raised $2.0 million in gross proceeds from a private placement, issuing common stock and warrants. This offering also has the potential to generate up to an additional $4.0 million upon cash exercise of the common warrants.
Analysis · TPST · Life Sciences
Tempest Therapeutics reported a substantial net loss for Q1 2026, primarily due to a significant non-cash expense related to its strategic CAR-T asset acquisition. The company continues to operate under a 'going concern' warning, highlighting its precarious financial position with only $1.8 million in cash at quarter-end. However, new liquidity relief from a related party, Factor Bioscience Inc., provides a critical, albeit temporary, boost to the company's cash runway, alongside a recent private placement. This indicates ongoing efforts to secure funding and advance its pipeline despite severe financial challenges.
At the time of this filing, TPST was trading at $1.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $30M. The 52-week trading range was $1.50 to $12.23. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.